Graybug Vision

General Information

We are a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. Our novel proprietary technologies are designed to release drugs in ocular tissue at a controlled rate for up to 12 months in order to improve patient compliance, reduce healthcare burdens and, ultimately, deliver better clinical outcomes. Our lead product candidate, GB-102, is an intravitreal injection of a microparticle depot formulation of sunitinib, a potent inhibitor of neovascular growth and permeability, which are leading causes of retinal disease. We are developing GB-102 as a once-every-six months intravitreal injection for the treatment of wet age-related macular degeneration, or wet AMD, and diabetic macular edema, or DME.

We are also using our proprietary technologies to develop GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy, or DR, as well as GB-401, an intravitreally injectable depot formulation of a beta-adrenergic blocking agent prodrug with a dosing regimen of once every six months or longer for the treatment of primary open-angle glaucoma, or POAG. 

Industry: Pharmaceuticals
Employees: 4
Founded: 2011
Contact Information
Address 275 Shoreline Drive, Suite 450 Redwood City, CA 94065
Phone Number (650) 487-2800
Web Address
View Prospectus: Graybug Vision
Financial Information
Market Cap $306.56mil
Revenues $0 mil (last 12 months)
Net Income $-43.6 mil (last 12 months)
IPO Profile
Symbol GRAY
Exchange NASDAQ
Shares (millions): 5.6
Price range $16.00 - $16.00
Est. $ Volume $90.0 mil
Manager / Joint Managers SVB Leerink/ Piper Sandler
CO-Managers Needham & Co./ Wedbush Securities
Expected To Trade: 9/25/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change